Key Takeaways from the Provided Text on GLP-1 Drug Spending in Medicaid
Here’s a breakdown of the key information from the provided text regarding GLP-1 (glucagon-like peptide-1) drug use and spending within Medicaid:
1. Dramatic Growth in Use & Spending:
* Prescriptions: GLP-1 prescriptions in Medicaid skyrocketed from approximately 1 million in 2019 to over 8 million in 2024.
* Gross Spending: Gross spending on these drugs increased ninefold, from about $1 billion in 2019 to almost $9 billion in 2024.
* Cost Per Prescription: The gross spending per GLP-1 prescription reached $1,000 in 2024.
* Continued Growth: Preliminary data suggests this rapid growth will continue into 2025.
2. Market Share & Leading Drugs:
* Small but Growing Share: While GLP-1s still represent a relatively small portion of total Medicaid prescriptions (1% in 2024, up from 0% in 2019), they account for a critically importent and rapidly growing share of spending (over 8% in 2024, up from 1% in 2019).
* Ozempic Dominance: Ozempic (semaglutide) is the leading GLP-1 drug, making up 39% of prescriptions and spending in 2024, surpassing Trulicity.
* Rapid Rise of Newer Drugs: Wegovy (also semaglutide) and Mounjaro (tirzepatide) saw prescriptions and spending more than double from 2023 to 2024. Zepbound (tirzepatide) experienced even more rapid growth, with a fivefold increase in prescriptions and spending.
3. Rebates & Pricing:
* Rebates Not Included: The reported spending figures do not account for rebates, which are ample for brand-name drugs in Medicaid.
* Novo Nordisk Transparency: Novo Nordisk (manufacturer of Ozempic and Wegovy) reports that rebates and fees account for about 40% of the drugs’ cost, and they expect this to increase.
* Price Agreements: Novo Nordisk and Eli Lilly (manufacturer of Mounjaro and Zepbound) have recently reached agreements with the Trump governance to lower prices.
4. Usage Breakdown & Data Limitations:
* Unknown Usage Patterns: Medicaid data currently cannot distinguish whether GLP-1s are being used for diabetes,cardiovascular disease,obesity,sleep apnea,or a combination of these conditions.
* Data Source: The analysis is based on State Drug Utilization Data (SDUD) from Medicaid.
* Limitations of the Data:
* the data doesn’t account for the number of days’ supply per prescription.
* Gross spending figures don’t include rebates.
* Data is updated quarterly,leading to potential variations in totals over time.
In essence, the text highlights a dramatic and costly increase in the use of GLP-1 drugs within Medicaid, driven by both increased utilization of existing drugs (Ozempic, Trulicity) and the introduction of newer medications (wegovy, Mounjaro, Zepbound). The rising costs are a significant concern, and the lack of clarity regarding why these drugs are being prescribed complicates efforts to address the issue.
